A sudden seasonal flu outbreak and an increase in Covid-19 cases have surprised many just as we were beginning to get used to the normalcy of a life without many constraints before the Covid virus.
An unavoidable flu wave generally coincides with a change in season. However, this season has witnessed an unanticipated increase in such cases-nearly doubling from last year in some areas-as well as harsher, Covid-like symptoms.
The spike of Covid-19 cases, the upcoming holiday season, and all of this together create a situation that specialists warn calls for ongoing precautions.
"Masks are the first line of defence against Covid-19 as well as other respiratory infections. With a spike in the number of infections, we must adhere to wearing masks when we step out in public areas. With the festive season right here and large gatherings inevitable, wearing masks are highly effective at reducing your risk of getting Covid as well as seasonal flu. Wearing the right kind of mask, the right way, is also extremely important," says Dr SC Ajmani, General Physician.
Your masks' kind and fit have a significant impact on how effective they are. According to research conducted by the Max Planck Institute for Dynamics and Self Organization in Germany, FFP2 masks that fit snugly offer 75 times more protection than surgical masks. By selecting these masks over common surgical or fabric masks, you greatly boost your protection and can leave the house more confidently, especially in crowded areas.
Protection from viruses, bacteria, dust, pollutants, allergens, and pollen (>= 0.3 micron) is offered by a BIS-approved FFP2 S mask like Savlon. These masks offer 95% protection from aerosols with particles larger than 0.3 micron. In comparison to standard masks, these masks include melt blown filters that are electro statically charged to provide enhanced filtering. The comfort and suitability of these masks for different skin types are also tested. Masks made with Savlon FFP2 S are BIS Certified.
According to BIS guidelines, each batch is put through rigorous testing for quality performance and efficacy. The effects of viruses, bacteria, dust, pollution, pollen, and allergies can be significantly minimised and the wearer's general health can be improved by donning a high-quality, properly fitted mask.
The correct masks are adjusted to perfectly fit on the bridge of your nose and to properly enclose your mouth and nose. We are aware that when an infected individual sneezes or coughs in a crowded environment, the Covid-19 virus as well as the seasonal influenza can spread quickly. First-level protection is unquestionably provided by donning a N95 or FFP2 S mask, especially for those with allergies, co-morbidities, impaired immune systems, or a higher propensity for experiencing severe symptoms.
The use of masks should become a way of life. We must continue using tried-and-true health strategies, like using masks in public. Keep your hygiene and health in mind.
Read More► Intermittent Fasting May Reduce Complications From Covid-19: Study
न्यूयॉर्क: शोधकर्ताओं का कहना है कि 60 साल या उससे अधिक आयु के मरीजों को जितना अधिक एंटीबायोटिक दिया जायेगा, उतना ही उनके इंफ्लेमेटरी बाउल डिजीज (आईबीडी) से ग्रसित होने की संभावना बढ़ती जायेगी। न्यूयॉर्क यूनिवर्सिटी के ग्रॉसमैन स्कूल ऑफ मेडिसिन के शोधकर्ता एडम एस फाये के अनुसार, 60 साल और उससे अधिक आयु के लोगों के क्रॉन बीमारी और अल्सरेटीव कोलाइटिस से ग्रसित होने में एंटीबायोटिक दवाओं के सेवन की भूमिका रही है।
शोध अध्ययन के दौरान 23 लाख मरीजों के रिकॉर्ड की समीक्षा की गई।
शोधकर्ताओं का कहना है कि दूसरे व्यस्कों में पर्यावरणीय कारक जेनेटिक्स से अधिक महत्वपूर्ण हैं।
उन्होंने कहा कि जब क्रॉन बीमारी और अल्सरेटीव कोलाइटिस से ग्रसित युवा मरीजों के रिकॉर्ड को देखा जाये तो पता चलेगा कि उनकी फैमिली हिस्ट्री मजबूत रही है। लेकिन अधिक आयु के लोगों के मामले में ऐसा नहीं है यानी पर्यावरण में कुछ ऐसा है जिससे यह हो रहा है।
शोधकर्ताओं ने डेनमार्क के नेशनल डाटाबेस का इस्तेमाल किया। यह सभी लोगों के मेडिकल रिकॉर्ड का डाटाबेस है। शोधकर्ताओं ने 2000 से 2018 के बीच आईबीडी से ग्रसित होने वाले 60 साल और उससे अधिक आयु के लोगों को लिखी जाने वाली दवाओं के रिकॉर्ड देखे।
शोधकर्ताओं ने देखा कि उन मरीजों को एंटीबायोटिक का कौन सा कोर्स किया है और उन्होंने हाल ही में कब एंटीबायोटिक ली थी।
उन्होंने पाया कि एंटीबायोटिक के इस्तेमाल से आईबीडी से ग्रसित होने की संभावना बढ़ जाती है और जैसे-जैसे मरीज अन्य एंटीबायोटिक का कोर्स करता है, वैसे-वैसे यह संभावना भी बढ़ती जाती है।
एक कोर्स के बाद मरीज के आईबीडी से ग्रसित होने की संभावना 27 प्रतिशत अधिक बढ़ जाती है। एंटीबायोटिक का दो कोर्स करने पर यह जोखिम 55 प्रतिशत और तीन कोर्स करने पर 67 प्रतिशत बढ़ जाती है।
चार कोर्स करने पर यह संभावना 96 प्रतिशत और पांच या उससे अधिक कोर्स करने पर 236 प्रतिशत बढ़ जाती है। (एजेंसी)
यह भी पढ़े► लिथियम की कम डोज किडनी के लिये वरदान: शोध
Prime Minister Narendra Modi on Wednesday announced a special Ayush mark for Ayush products among many new initiatives for Ayush sector, on the occasion of Global Ayush Investment & Innovation Summit 2022.
The Prime Minister on Wednesday inaugurated the three-day Global Ayush Investment & Innovation Summit 2022 at Gandhinagar in the presence of the Prime Minister of Mauritius Pravind Kumar Jugnauth, WHO Director General, Tedros Adhanom Ghebreyesus, Union Health Minister Mansukh Mandaviya, Union Ayush Minister Sarbananda Sonowal, Gujarat Chief Minister Bhupendra Patel and others.
In his inaugural address, Modi said: "We are already witnessing unprecedented growth in the production of Ayush medicines, supplements and cosmetics. In 2014, where the Ayush sector was less than $3 billion, today it has increased to more than $18 billion. An unprecedented efforts has been made in the past years to promote the export of Ayush products."
Along with first being a special Ayush mark for Ayush products, Modi announced many other initiatives for Ayush sector. A new category named 'Ayush Aahar' was announced which will greatly facilitate the producers of herbal nutritional supplements.
Further, another major initiative for foreign nationals who want to come to India to take advantage of Ayush therapy was announced. India will soon introduce a special Ayush visa category.
Describing the current age of the era of unicorns, the Prime Minister informed that in the year 2022 itself, so far 14 start-ups from India have joined the Unicorn Club. "I am sure unicorns will emerge from our Ayush start-ups very soon", he stated.
Prime Minister also announced launch of Ayush Export Promotion Council and four Ayush ICT initiatives which includes Ayush Information Hub, AyuSoft, Ayush Next and Ayush GIS.
The Prime Minister also released a comic book named 'Professor Ayushman', which describes how Ayush systems and products helped in fighting not only Covid-19 but other diseases also.
Addressing the session, Tedros said that the Ayush sector is growing significantly by 17 per cent per year since 2014.
He said that Ayush industry is projected to reach $23 billion by the end of this year.
"We are exploring innovative study designs and the use of artificial intelligence to document the impact of traditional medicine practices, in cases when standard randomised trials are not possible or are difficult to undertake.
"Strengthening the evidence base of traditional medicine should facilitate its use by communities, to promote better health outcomes, economic benefits and overall impact," he added.
Read More► PM Launches Ayush Visa for Medical Tourists
London: A psychedelic compound found in psilocybin, commonly known as magic mushrooms, can help to "open up" depressed people's brains, enabling brain regions to talk more freely to one another, finds a study.
Psilocybin is one of a number of psychedelics being explored as a potential therapy for psychiatric disorders. Several studies have trialled a synthesised form of the drug to treat patients with depression and anxiety, with promising results.
A team at Imperial College London's Centre for Psychedelic Research believes to have untangled how psilocybin exerts its therapeutic effects on the brain.
The new results, taken from two combined studies including about 60 adults, reveal that people who responded to psilocybin-assisted therapy showed increased brain connectivity not just during their treatment, but up to three weeks afterwards.
This "opening up" effect was associated with self-reported improvements in their depression.
However, similar changes in brain connectivity were not seen in those treated with a conventional antidepressant (called escitalopram), suggesting the psychedelic works differently in treating depression.
According to the team, the findings, published in the journal Nature Medicine, are a promising advance for psilocybin therapy, with the effects replicated across two studies.
They explain that patterns of brain activity in depression can become rigid and restricted, and that psilocybin could potentially help the brain to break out of this rut in a way that traditional therapies cannot.
"The effect seen with psilocybin is consistent across two studies, related to people getting better, and was not seen with a conventional antidepressant," said Professor Robin Carhart-Harris, from University of California, San Francisco.
"In previous studies we had seen a similar effect in the brain when people were scanned whilst on a psychedelic, but here we're seeing it weeks after treatment for depression, which suggests a acarry over' of the acute drug action," Carhart-Harris, who was former Head of the Imperial Centre for Psychedelic Research.
The researchers added that while follow-up data is still being analysed for participants, initial changes in brain activity one day following treatment were a good predictor of whether a person would still show improvement at six months.
However, they cautioned that patients with depression should not attempt to self-medicate with psilocybin, as taking magic mushrooms or psilocybin in the absence of safeguards may not have a positive outcome. (Agency)
Read More► Drinking Coffee Could Benefit Heart, Help You Live Longer: Study
Regular use of viagra, used to treat erectile dysfunction, can harm your vision leaving you blind, a study has claimed. Researchers from the University of British Columbia in Canada have found that people regularly taking the common erectile dysfunction pill may be at increased risk of sudden losses of vision, flashes of light, and dark spots, Daily Mail reported.
The reason may be an increase in blood flow to the genitals which could be hindering its supply to the eyes, the researchers said. The team also named other impotence medicines - Cialis, Levitra and Spedra - as being potential triggers of eye problems.
Regular users of the impotence pills are 85 per cent more likely to develop serious vision-robbing conditions, revealed the study published in JAMA Ophthalmology.
"These are rare conditions, and the risk of developing one remains very low for any individual user. However, the sheer number of prescriptions dispensed each month in the US - about 20 million - means that a significant number of people could be impacted," lead researcher Dr Mahyar Etminan, an ophthalmologist at the varsity, was quoted as saying.
"Regular users who find any changes in their vision should take it seriously and seek medical attention," he suggested.
In the study, the team analysed insurance claim records of 213,033 men using ED pills: 123,347 men took sildenafil - the medication branded as Viagra by Pfizer, 78,609 were on tadalafil (Cialis); 6,604 took vardenafil (Levitra), and 4,473 were on avanfil (Spedra), the report said.
The team followed the claim records from 2006 to 2020 to see which ones went on to develop eye conditions. None of the men had suffered eye problems in the year before they became regular users of the medication.
They found that regular intake of one of the medications was 158 per cent more likely to lead to serious retinal detachment. It occurs when a collection of fluid builds up behind the back of the eye and causes the sudden appearance of spots in the field of vision and flashes of light.
The men were 102 per cent more likely to suffer ischemic optic neuropathy - a compromised blood supply to the optic nerve. The condition causes a loss of central vision. And they were 44 per cent more likely to develop retinal vascular occlusion - a type of blood clot in the retina. People with it suffer a sudden loss of vision and dark spots or 'floaters' in their vision, the report said. (Agency)
Read More► Sleeping With Even Low Light is Harmful for Health: Study
New York: Next time you order a pizza or whip up a creamy risotto, go ahead and load on the mushrooms.
Adding more edible fungi into your diet may be one way to counteract the health risks associated with the Western-style diet (WSD), which often features an abundance of fatty foods and added sugars.
Fatty and sugary foods contribute to obesity, Type 2 diabetes, heart disease, certain cancers and a host of other chronic health issues.
Researchers at the University of Massachusetts Amherst investigated how modifiable factors such as diet and lifestyle and their metabolically related gene variants interact to influence the development of chronic diseases.
The team focused on identifying metabolic targets to prevent or treat obesity and insulin resistance.
"Intestinal dysfunction is thought to be one of the underlying mechanisms that contribute so significantly to the development of WSD-related diseases," said nutritionist Zhenhua Liu, Associate Professor in the School of Public Health and Health Sciences at the varsity.
In a previous research, the team found that a rarely studied bacterium, Turicibacter, is almost completely depleted by high fat diet-induced obesity, but not genetic obesity.
But they found that sundried oyster mushrooms, found throughout most of the world, possesses a unique dietary composition rich with multiple nutrients lacking in the Western-style diet, such as dietary fibre and vitamin D.
"It's a perfect supplement as a natural whole food to improve the quality of Western-style diets, with the added benefit of improving our overall gut health," Liu said.
Liu's study will examine the cellular and molecular mechanisms by which these mushrooms improve gut health.
Specifically, the team will examine the mushroom's interaction with Turicibacter in Western-style diet-related intestinal dysfunction and the effect it may have on reshaping gut microbiome.
"We hope this study will provide the mechanistic understanding of the role of Turicibacter in dietary obesity and gut health," Liu said.
"It will also provide important insight into mushrooms as a whole-food approach to improve the quality of WSD and gut health."
Read More► Diets That Don't Work for Women
Dear Patron, Please provide additional information to validate your profile and continue to participate in engagement activities and purchase medicine.